NRx Pharmaceuticals Completes Ketamine Validation Ahead of FDA Goal Date

Key Facts

1NRx Pharmaceuticals announced the completion of three process validation lots of preservative-free Ketamine under commercial conditions.

2Process validation is the final step required to demonstrate compliance with FDA Good Manufacturing Practices (GMP).

3The company is anticipating a November 10 GDUFA Goal Date following the validation completion.

NRx Pharmaceuticals announced the completion of three process validation lots of preservative-free Ketamine produced under commercial conditions. According to a company statement via GlobeNewswire, this validation is the final step required to demonstrate compliance with FDA Good Manufacturing Practices (GMP).

The company is now anticipating a GDUFA Goal Date on November 10, 2026, following the successful validation. NRXP closed at $2.6 on October 16, 2026, having reached a day high of $2.76 and a low of $2.57 during that session.